Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am Heart J ; 219: 9-20, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-31710844

RESUMO

OBJECTIVE: An increasingly recognized prognostic factor for out-of-hospital-cardiac-arrest (OHCA) patients is the ischemia-reperfusion injury after restored blood circulation. Endothelial injury is common in patients resuscitated from cardiac arrest and is associated with poor outcome. This study was designed to investigate if iloprost infusion, a prostacyclin analogue, reduces endothelial damage in OHCA patients. METHODS: 50 patients were randomized in a placebo controlled double-blinded trial and allocated 1:2 to 48-hours iloprost infusion, (1 ng/kg/min) or placebo (saline infusion). Endothelial biomarkers (soluble thrombomodulin (sTM), sE-selectin, syndecan-1, soluble vascular endothelial growth factor (sVEGF), vascular endothelial cadherine (VEcad), nucleosomes) and sympathoadrenal activation (epinephrine/norepinephrine) from baseline to 48 and 96-hours were evaluated. RESULTS: Iloprost infusion did not influence endothelial biomarkers by the 48-hour endpoint. A rebound effect was observed with higher biomarker plasma values in the iloprost group (sTM p=0.02; Syndecan p=0.004; nucleosomes p<0.001; VEcad p<0.03) after 96-hours. There was a significant difference in 180-day mortality in favor of placebo. There was no difference regarding total adverse events between groups (p=0.73). Two patients were withdrawn in the iloprost group due to hypotension. CONCLUSIONS: The administration of low-dose iloprost (1ng/kg/min) to OHCA patients did not significantly influence endothelial biomarkers as measured by the 48- hour endpoint. A rebound effect was however observed in the 96-hour statistical model, with increasing endothelial biomarker levels after cessation of the iloprost-infusion.


Assuntos
Endotélio Vascular/efeitos dos fármacos , Iloprosta/administração & dosagem , Parada Cardíaca Extra-Hospitalar/terapia , Síndrome Pós-Parada Cardíaca/tratamento farmacológico , Vasodilatadores/administração & dosagem , Idoso , Antígenos CD/sangue , Biomarcadores/sangue , Temperatura Corporal , Caderinas/sangue , Método Duplo-Cego , Selectina E/sangue , Endotélio Vascular/metabolismo , Endotélio Vascular/fisiopatologia , Epinefrina/sangue , Feminino , Humanos , Iloprosta/efeitos adversos , Masculino , Pessoa de Meia-Idade , Norepinefrina/sangue , Nucleossomos , Parada Cardíaca Extra-Hospitalar/sangue , Parada Cardíaca Extra-Hospitalar/mortalidade , Projetos Piloto , Síndrome Pós-Parada Cardíaca/sangue , Síndrome Pós-Parada Cardíaca/mortalidade , Solução Salina/administração & dosagem , Tamanho da Amostra , Sindecana-1/sangue , Tromboelastografia , Trombomodulina/sangue , Fatores de Tempo , Vasodilatadores/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...